Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Open Orphan Plc ( (GB:HVO) ) has provided an update.
hVIVO plc announced positive topline results from a Phase 2b field study conducted for Cidara Therapeutics, focusing on the efficacy of CD388, a non-vaccine preventative for seasonal influenza. hVIVO was responsible for recruiting participants and conducting virology and immunology laboratory services. The study, which met its primary and secondary endpoints with statistical significance, involved 817 participants and demonstrated a significant reduction in influenza-like illness among those administered CD388. The success of this trial underscores hVIVO’s capability in managing large-scale field studies and highlights its role in advancing novel preventative treatments for influenza.
The most recent analyst rating on (GB:HVO) stock is a Buy with a £35.00 price target. To see the full list of analyst forecasts on Open Orphan Plc stock, see the GB:HVO Stock Forecast page.
Spark’s Take on GB:HVO Stock
According to Spark, TipRanks’ AI Analyst, GB:HVO is a Neutral.
The overall score reflects strong valuation and positive corporate events, which are the most significant factors. While financial performance is strong, technical analysis indicates bearish trends. The exclusion of earnings call data slightly reduces the weight of other components.
To see Spark’s full report on GB:HVO stock, click here.
More about Open Orphan Plc
hVIVO plc is a full-service early-phase Contract Research Organisation (CRO) and the global leader in human challenge trials. The company provides end-to-end clinical development services to a diverse client base, including seven of the world’s ten largest biopharma companies. hVIVO specializes in conducting human challenge trials across multiple infectious and respiratory indications and offers comprehensive virology and immunology laboratory services. The company operates a large quarantine facility in London and has a German subsidiary, CRS, with a 120-bed capacity for early-phase clinical trial services.
Average Trading Volume: 3,604,318
Technical Sentiment Signal: Sell
Current Market Cap: £75.57M
For detailed information about HVO stock, go to TipRanks’ Stock Analysis page.